We are live on ! Find out more
RGLS

Regulus Therapeutics
RGLS

Delisted

RGLS was delisted on the 24th of June, 2025.

Back to rankings

46 hedge funds and large institutions have $22.4M invested in Regulus Therapeutics in 2017 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.04% more ownership

Funds ownership: 0.32% → 0.36% (+0.04%)

21% less funds holding

Funds holding: 58 → 46 (-12)

21% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 14

32% less capital invested

Capital invested by funds: $33.1M → $22.4M (-$10.7M)

52% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 21

53% less call options, than puts

Call options by funds: $19K | Put options by funds: $40K

Holders
46
Holders Change
-12
Holders Change %
-20.69%
% of All Funds
1.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
11
Reduced
14
Closed
21
Calls
$19K
Puts
$40K
Net Calls
-$21K
Net Calls Change
+$72K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$3.69M
2
EC
EcoR1 Capital
California
+$3.06M
3
Millennium Management
Millennium Management
New York
+$654K
4
Goldman Sachs
Goldman Sachs
New York
+$335K
5
LP
LMR Partners
United Kingdom
+$231K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$2.22M
2
State Street
State Street
Massachusetts
-$762K
3
Northern Trust
Northern Trust
Illinois
-$473K
4
TCIM
TIAA CREF Investment Management
New York
-$203K
5
Renaissance Technologies
Renaissance Technologies
New York
-$195K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$7.86M +$52.1K +312 +0.5%
EC
2
EcoR1 Capital
California
$3.66M +$3.06M +18,327 +146%
BI
3
BVF Inc
California
$3.23M +$3.69M +22,132 +426%
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.45M -$76K -455 -4%
SDIC
5
South Dakota Investment Council
South Dakota
$1.31M – – –
Wells Fargo
6
Wells Fargo
California
$688K -$117K -700 -11%
RPAM
7
Rhenman & Partners Asset Management
Sweden
$585K – – –
BlackRock
8
BlackRock
New York
$522K -$2.22M -13,290 -75%
Millennium Management
9
Millennium Management
New York
$463K +$654K +3,919 New
Goldman Sachs
10
Goldman Sachs
New York
$363K +$335K +2,007 +189%
ARTA
11
A.R.T. Advisors
New York
$255K -$23.9K -143 -6%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$208K -$75.4K -452 -20%
WS
13
Wedbush Securities
California
$197K +$25.9K +155 +10%
Royal Bank of Canada
14
Royal Bank of Canada
Ontario, Canada
$182K +$27.7K +166 +12%
California Public Employees Retirement System
15
California Public Employees Retirement System
California
$175K – – –
LP
16
LMR Partners
United Kingdom
$164K +$231K +1,386 New
ECM
17
Element Capital Management
New York
$161K +$228K +1,363 New
PP
18
Paloma Partners
Connecticut
$144K +$203K +1,217 New
GCP
19
GSA Capital Partners
United Kingdom
$139K +$196K +1,173 New
QIM
20
Quantitative Investment Management
Virginia
$103K +$146K +875 New
Northern Trust
21
Northern Trust
Illinois
$77K -$473K -2,836 -81%
Morgan Stanley
22
Morgan Stanley
New York
$69K +$11K +66 +13%
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
$63K +$17.7K +106 +25%
Barclays
24
Barclays
United Kingdom
$49K +$9.18K +55 +15%
Squarepoint
25
Squarepoint
New York
$44K +$61.8K +370 New
1
2 3

RGLS Hedge Fund Activity: Q2 2017 in Review

46 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q2 2017, worth a combined $22.4M — down 32% from $33.1M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of RGLS and 10 opened new positions — a net loss of 11 holders — while 14 trimmed existing stakes and 11 added.

The largest buyer was BVF Inc, adding an estimated $3.69M. The largest seller was BlackRock, cutting an estimated $2.22M.

  • 46 institutional investors held Regulus Therapeutics (RGLS) as of Q2 2017, down from 58 in Q1 2017.
  • Funds reported $22.4M of Regulus Therapeutics stock for Q2 2017, down 32% quarter-over-quarter.
  • 10 funds opened new Regulus Therapeutics positions in Q2 2017 and 21 closed out, a net change of -11 holders.
  • The largest Regulus Therapeutics buyer in Q2 2017 was BVF Inc, an estimated $3.69M added.
  • The largest Regulus Therapeutics seller in Q2 2017 was BlackRock, an estimated $2.22M sold.

Based on aggregated 13F filings for Q2 2017.